The Effects of Adding TCM-700C on the Standard Combination Treatment for Patients With Genotype 1 Hepatitis C Infection
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effectiveness of TCM-700C as an add-on
treatment to the combination drug therapy (Peginterferon α-2b plus Ribavirin) for patients
with genotype 1 chronic hepatitis C infections. This will be demonstrated by a higher
sustained virologic response rate, defined as the absence of detectable HCV RNA 24 weeks
after the termination of combinational drug treatment, compared with the placebo add-on.